15% OFF $200+· CodeSTOCKUP15
Ends November 30Shop now
Lot certificates published
Plain, secure packaging
Purely Peptides
Research Catalog
Catalog/Tirzepatide
Tirzepatide
#1019
Lyophilized Peptide

Tirzepatide 60mg

High-concentration tirzepatide (60mg) lyophilized vial for research applications requiring larger reagent quantities or extended in-vitro protocols. Same dual GIP/GLP-1 receptor agonist compound as the 30mg listing; the higher concentration reduces reconstitution frequency. Tirzepatide is an acylated peptide agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the GLP-1 receptor (GLP-1R). In experimental receptor systems it shows greater relative engagement of GIPR and biased signaling at GLP-1R, favoring cAMP generation over beta-arrestin recruitment, with less receptor internalization than native GLP-1. Its C20 fatty-diacid modification promotes albumin binding and prolonged in-vitro stability. Supplied strictly for in-vitro research and laboratory use only. Not for human or animal use.

Strength

10mg$74.9915mg$79.9930mg$89.9940mg$109.9960mg$129.99

Select Option

Single (60mg)$129.99

2+ save 5% · 5+ save 10% · 10+ save 20%

Quantity

1
= $129.99
Buy now
  • Free Priority shipping on US orders over $100
  • Ships same day on orders before 2 PM MST
  • Plain, secure packaging
  • Reported measurements · lot TIR-20260811-01Bioviridian Inc. · COA7921: purity 99.86%; content 61.23 mg.Krause Analytical LLC · sample 59abg6p · Lab #214172: purity >99.9%; content 63.6 mg.Krause Analytical LLC · sample fwpftwh · Lab #214173: purity >99.9%; content 60.5 mg.
  • Stock-solution arithmetic — Tirzepatide concentration calculator

Batch Tracking

Batch #

TIR-20260811-01

Tested

2026-08-23

Purity

Bioviridian Inc. · COA7921: purity 99.86%; content 61.23 mg.Krause Analytical LLC · sample 59abg6p · Lab #214172: purity >99.9%; content 63.6 mg.Krause Analytical LLC · sample fwpftwh · Lab #214173: purity >99.9%; content 60.5 mg.

Method

RP-HPLC (214 nm)

View Certificate of Analysis
Telegram - @purely_peptides orders@purelypeptides.org

Mechanism of Action

In engineered receptor-expressing cell systems, tirzepatide activates GIPR and GLP-1R. Willard et al. (2020) reported GIPR signaling resembling native GIP, while GLP-1R signaling favored cAMP generation over beta-arrestin recruitment and produced less GLP-1R internalization than GLP-1.

Properties

CAS Number

2023788-19-2

Molecular Formula

C₂₂₅H₃₄₈N₄₈O₆₈

Molecular Weight

4813.53 Da

Half-Life

~5 days (human)

Storage

Store lyophilized at -20°C. Reconstituted at 2-8°C, use within 30 days.

Shipping & Delivery

  • Same-day dispatch on orders placed before 2 PM MST (Arizona — no daylight saving).
  • US shipping from $5. Free Priority on orders $100+ (before discounts).
  • Plain, unmarked packaging — no branding or product names on the outside.
  • Ships to all 50 states, DC, Puerto Rico & the U.S. Virgin Islands; tracking emailed on every order.
Full shipping details

Quality & Testing

  • Independently tested by Bioviridian Inc. — identity by LC-MS/MS, purity by RP-HPLC (214 nm).
  • Reported measurements on lot TIR-20260811-01:Bioviridian Inc. · COA7921: purity 99.86%; content 61.23 mg.Krause Analytical LLC · sample 59abg6p · Lab #214172: purity >99.9%; content 63.6 mg.Krause Analytical LLC · sample fwpftwh · Lab #214173: purity >99.9%; content 60.5 mg.
  • USA-based; dispatched from Phoenix, Arizona.
  • Supplied strictly for in-vitro laboratory research — not for human use.

Additional laboratory results (2)

Krause Analytical LLC · sample 59abg6p · Lab #214172

Tested by Krause Analytical LLC; commissioned through Finnrick.

The certificate’s Batch/Lot field shows the Finnrick sample code 59abg6p. We list this result under lot TIR-20260811-01.

Chromatographic purity
>99.9%
Method: HPLC-UV/MS
Measured content
63.6 mg
Method: HPLC-UV-MS
Identity (mass spectral match)
ID Confirmed
Method: HPLC-UV-MS
Label claim
60 mg
% of label, as printed
106.0
COC#
145871
Received
2026-09-18
Analyzed
2026-09-24
Report issued
2026-10-01
Laboratory address
8127 Mesa Drive Suite B-206, Austin, TX 78759
Laboratory director
Mark C. Krause
PDF SHA-256
8b2661825c8ae4ea405746eca21d5705db3a52e145376b26963a4a789961218e
Original full certificate (PDF) · 59abg6p

Krause Analytical LLC · sample fwpftwh · Lab #214173

Tested by Krause Analytical LLC; commissioned through Finnrick.

The certificate’s Batch/Lot field shows the Finnrick sample code fwpftwh. We list this result under lot TIR-20260811-01.

Chromatographic purity
>99.9%
Method: HPLC-UV/MS
Measured content
60.5 mg
Method: HPLC-UV-MS
Identity (mass spectral match)
ID Confirmed
Method: HPLC-UV-MS
Label claim
60 mg
% of label, as printed
100.9
COC#
145871
Received
2026-09-18
Analyzed
2026-09-24
Report issued
2026-10-01
Laboratory address
8127 Mesa Drive Suite B-206, Austin, TX 78759
Laboratory director
Mark C. Krause
PDF SHA-256
49d92f213eb97864bcebb5c932e0325ceb56616fefdd97eeb34144ca7d885af7
Original full certificate (PDF) · fwpftwh
Lot TIR-20260811-01 · certificatesBioviridian Inc. · COA7921: purity 99.86%; content 61.23 mg.Krause Analytical LLC · sample 59abg6p · Lab #214172: purity >99.9%; content 63.6 mg.Krause Analytical LLC · sample fwpftwh · Lab #214173: purity >99.9%; content 60.5 mg.

Research Applications

1Long-term in-vitro protocol studies
2Large reagent-quantity research
3Dose-response characterization
4Extended metabolic-pathway endpoint monitoring

References & Citations

(4)
1

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.

Schneck K, Urva S

CPT Pharmacometrics Syst Pharmacol (2024)PMID: 38356317 DOI
2

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Willard FS, Douros JD, Gabe MBN, et al.

JCI Insight (2020)PMID: 32730231 DOI
3

Structural determinants of dual incretin receptor agonism by tirzepatide

Sun B, Willard FS, Feng D, et al.

Proc Natl Acad Sci USA (2022)PMID: 35333651 DOI
4

GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice

Samms RJ, Christe ME, Collins KA, et al.

J Clin Invest (2021)PMID: 34003802 DOI

Other strengths

Tirzepatide 10mg

#1061

$74.99

Tirzepatide 15mg

#1064

$79.99

Tirzepatide 30mg

#1002

$89.99

Tirzepatide 40mg

#1065

$109.99

Research Use Only

This product is intended strictly for in-vitro research, educational, and laboratory use. Not for human consumption. The information provided is based on published research and does not constitute medical advice.

Research reference

A published identity, mechanism, and bibliography record corresponds to this catalog entry.

Research reference: Tirzepatide

More references from the Research Library (5)

Further papers cited in the Library's Tirzepatide record, each checked against PubMed. They describe the compound in research settings and are not statements about this product. See the full record for its identity, structure and complete bibliography.

  1. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.

    Coskun T, Sloop KW, Loghin C, et al.

    Molecular metabolism (2018)In vitro · Animal · Human participants (interventional)PMID 30473097
  2. Pharmacology, physiology, and mechanisms of incretin hormone action.

    Campbell JE, Drucker DJ

    Cell metabolism (2013)Review articlePMID 23684623
  3. How May GIP Enhance the Therapeutic Efficacy of GLP-1?

    Samms RJ, Coghlan MP, Sloop KW

    Trends in endocrinology and metabolism: TEM (2020)Review articlePMID 32396843
  4. Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein.

    Zhang Y, Sun B, Feng D, et al.

    Nature (2017)In vitroPMID 28538729
  5. Structural basis for ligand recognition of incretin receptors.

    Underwood CR, Parthier C, Reedtz-Runge S

    Vitamins and hormones (2010)Review articlePMID 21094903